PL3256125T3 - Schemat dawkowania ponesimodu, selektywnego agonisty receptora s1p1 - Google Patents

Schemat dawkowania ponesimodu, selektywnego agonisty receptora s1p1

Info

Publication number: PL3256125T3
Authority: PL; Poland
Prior art keywords: ponesimod; selective; receptor agonist; dosing regimen; regimen
Prior art date: 2014-12-11

Application number

PL15807916T

Other languages

English (en)

Inventor

Jasper Dingemanse

Matthias Hoch

Andreas Krause

Original Assignee

Actelion Pharmaceuticals Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-12-11

Filing date

2015-12-10

Publication date

2022-05-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54843844&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3256125(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-12-10 Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd

2022-05-09 Publication of PL3256125T3 publication Critical patent/PL3256125T3/pl

Links

102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 title 1
108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 title 1
LPAUOXUZGSBGDU-STDDISTJSA-N chembl1096146 Chemical compound O=C1N(C=2C(=CC=CC=2)C)C(=N/CCC)/S\C1=C/C1=CC=C(OC[C@H](O)CO)C(Cl)=C1 LPAUOXUZGSBGDU-STDDISTJSA-N 0.000 title 1
229950009275 ponesimod Drugs 0.000 title 1
239000000018 receptor agonist Substances 0.000 title 1
229940044601 receptor agonist Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Emergency Medicine (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Physical Education & Sports Medicine (AREA)
Transplantation (AREA)
Endocrinology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Ophthalmology & Optometry (AREA)
Hematology (AREA)
Oncology (AREA)
Otolaryngology (AREA)

PL15807916T 2014-12-11 2015-12-10 Schemat dawkowania ponesimodu, selektywnego agonisty receptora s1p1 PL3256125T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
EP2014077469		2014-12-11
EP2015058202		2015-04-15
EP15807916.0A EP3256125B1 (en)	2014-12-11	2015-12-10	Dosing regimen for ponesimod, a selective s1p1 receptor agonist
PCT/EP2015/079208 WO2016091996A1 (en)	2014-12-11	2015-12-10	Dosing regimen for a selective s1p1 receptor agonist

Publications (1)

Publication Number	Publication Date
PL3256125T3 true PL3256125T3 (pl)	2022-05-09

Family

ID=54843844

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL15807916T PL3256125T3 (pl)	2014-12-11	2015-12-10	Schemat dawkowania ponesimodu, selektywnego agonisty receptora s1p1

Country Status (31)

Country	Link
US (4)	US10220023B2 (pl)
EP (2)	EP3256125B1 (pl)
JP (1)	JP6244497B1 (pl)
KR (4)	KR20200013086A (pl)
CN (2)	CN117137912A (pl)
AU (2)	AU2015359346B2 (pl)
CA (1)	CA2968180C (pl)
CL (1)	CL2017001457A1 (pl)
CY (1)	CY1125170T1 (pl)
DK (1)	DK3256125T3 (pl)
EA (1)	EA036075B1 (pl)
ES (1)	ES2909071T3 (pl)
FR (1)	FR22C1021I2 (pl)
HR (1)	HRP20220359T8 (pl)
HU (2)	HUE057865T2 (pl)
IL (1)	IL252727B (pl)
LT (2)	LT3256125T (pl)
MX (2)	MX2017007638A (pl)
MY (1)	MY188764A (pl)
NL (1)	NL301174I2 (pl)
NO (1)	NO2022023I1 (pl)
PH (1)	PH12017501059A1 (pl)
PL (1)	PL3256125T3 (pl)
PT (1)	PT3256125T (pl)
RS (1)	RS63048B1 (pl)
SG (1)	SG11201704563RA (pl)
SI (1)	SI3256125T1 (pl)
TW (1)	TW201625242A (pl)
UA (1)	UA122064C2 (pl)
WO (1)	WO2016091996A1 (pl)
ZA (1)	ZA201704624B (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI0909625B1 (pt)	2008-03-17	2021-09-08	Actelion Pharmaceuticals Ltd	Agonista seletivo do receptor s1p1 para o uso como um medicamento, uso de um agonista seletivo do receptor s1p1 e kit contendo diferentes unidades de medicação de um agonista seletivo do receptor s1p1
EP3256125B1 (en)	2014-12-11	2022-01-26	Actelion Pharmaceuticals Ltd	Dosing regimen for ponesimod, a selective s1p1 receptor agonist
MA41139A (fr)	2014-12-11	2017-10-17	Actelion Pharmaceuticals Ltd	Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
JOP20190207A1 (ar) *	2017-03-14	2019-09-10	Actelion Pharmaceuticals Ltd	تركيبة صيدلانية تشتمل على بونيسيمود
US11186556B1 (en)	2018-10-16	2021-11-30	Celgene Corporation	Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof
US11014940B1 (en)	2018-10-16	2021-05-25	Celgene Corporation	Thiazolidinone and oxazolidinone compounds and formulations
US11014897B1 (en)	2018-10-16	2021-05-25	Celgene Corporation	Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof
US11013723B1 (en)	2018-10-16	2021-05-25	Celgene Corporation	Solid forms of a thiazolidinone compound, compositions and methods of use thereof
KR20220035924A (ko)	2019-07-22	2022-03-22	액테리온 파마슈티칼 리미티드	다발성 경화증을 치료하는 방법
AU2020372647A1 (en)	2019-10-31	2022-06-16	Idorsia Pharmaceuticals Ltd	Combination of a CXCR7 antagonist with an S1P1 receptor modulator
AU2021232637A1 (en)	2020-03-06	2022-09-22	Actelion Pharmaceuticals Ltd	Methods of slowing brain volume loss
EP4308061A1 (en)	2021-03-17	2024-01-24	Actelion Pharmaceuticals Ltd.	Pharmaceutical dosage system
CA3220723A1 (en)	2021-10-11	2023-04-20	Allitia DIBERNARDO	Methods of treating multiple sclerosis
CA3221343A1 (en) *	2021-10-11	2023-04-20	Allitia DIBERNARDO	Methods of treating multiple sclerosis
US20230114486A1 (en)	2021-10-11	2023-04-13	Actelion Pharmaceuticals Ltd	Methods Of Treating Multiple Sclerosis
CA3220715A1 (en)	2021-10-11	2023-04-20	Krista Spiller	Methods of treating multiple sclerosis
CA3220549A1 (en)	2021-11-05	2023-05-11	Allitia DIBERNARDO	Methods for treating multiple sclerosis
CA3220702A1 (en)	2022-02-11	2023-08-17	Actelion Pharmaceuticals Ltd	Methods of slowing an increase in brain ventricular volume

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0217152D0 (en)	2002-07-24	2002-09-04	Novartis Ag	Organic compounds
RU2379299C2 (ru)	2003-11-21	2010-01-20	Актелион Фармасьютиклз Лтд	Производные 5-(бенз-(z)-илиден)тиазолидин-4-она и их применение в качестве иммуносупрессорных агентов
USRE43833E1 (en)	2003-11-21	2012-11-27	Actelion Pharmaceuticals Ltd.	Thiazolidin-4-one derivatives
BRPI0518674A2 (pt)	2004-11-29	2008-12-02	Novartis Ag	regime de dosagem de um agonista de receptor s1p
US7879821B2 (en)	2006-01-26	2011-02-01	University Of Medicine And Dentistry Of New Jersey	Method for modulating inflammatory responses by altering plasma lipid levels
EP2489662B1 (en)	2006-11-23	2014-08-06	Actelion Pharmaceuticals Ltd.	Intermediates of a new process for the preparation of 5-benzylidene-2-alkylimino-3-phenylthiazolidin-4-one derivatives
US8912340B2 (en)	2006-11-23	2014-12-16	Actelion Pharmaceuticals Ltd.	Process for the preparation of 2-imino-thiazolidin-4-one derivatives
BRPI0909625B1 (pt) *	2008-03-17	2021-09-08	Actelion Pharmaceuticals Ltd	Agonista seletivo do receptor s1p1 para o uso como um medicamento, uso de um agonista seletivo do receptor s1p1 e kit contendo diferentes unidades de medicação de um agonista seletivo do receptor s1p1
GB0819182D0 (en)	2008-10-20	2008-11-26	Actelion Pharmaceuticals Ltd	Crystalline forms
CA2747992C (en)	2008-12-22	2017-11-07	Novartis Ag	Dosage regimen of an s1p receptor agonist
BRPI0923500A2 (pt)	2008-12-22	2018-05-29	Novartis Ag	uso e composição farmacêutica compreendendo agonista ou modulador do receptor s1p, e kit.
RS60408B1 (sr)	2012-08-17	2020-07-31	Actelion Pharmaceuticals Ltd	Postupak za pripremanje (2z,5z)-5-(3-hloro-4-((r)-2,3-dihidroksipropoksi)benziliden)-2-(propilimino)-3-(o-tolil)tiazolidin-4-ona i međujedinjenja upotrebljena u pomenutom postupku
EP3256125B1 (en)	2014-12-11	2022-01-26	Actelion Pharmaceuticals Ltd	Dosing regimen for ponesimod, a selective s1p1 receptor agonist
MA41139A (fr)	2014-12-11	2017-10-17	Actelion Pharmaceuticals Ltd	Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1

2015
- 2015-12-10 EP EP15807916.0A patent/EP3256125B1/en active Active
- 2015-12-10 MX MX2017007638A patent/MX2017007638A/es unknown
- 2015-12-10 EA EA201791286A patent/EA036075B1/ru unknown
- 2015-12-10 DK DK15807916.0T patent/DK3256125T3/da active
- 2015-12-10 CA CA2968180A patent/CA2968180C/en active Active
- 2015-12-10 KR KR1020207002611A patent/KR20200013086A/ko not_active Application Discontinuation
- 2015-12-10 SI SI201531811T patent/SI3256125T1/sl unknown
- 2015-12-10 CN CN202310732054.6A patent/CN117137912A/zh active Pending
- 2015-12-10 WO PCT/EP2015/079208 patent/WO2016091996A1/en active Application Filing
- 2015-12-10 MX MX2020011182A patent/MX2020011182A/es unknown
- 2015-12-10 UA UAA201707086A patent/UA122064C2/uk unknown
- 2015-12-10 US US15/534,929 patent/US10220023B2/en active Active
- 2015-12-10 CN CN201580067209.2A patent/CN106999461A/zh active Pending
- 2015-12-10 KR KR1020177018950A patent/KR102427123B1/ko active IP Right Grant
- 2015-12-10 TW TW104141578A patent/TW201625242A/zh unknown
- 2015-12-10 HR HRP20220359TT patent/HRP20220359T8/hr unknown
- 2015-12-10 ES ES15807916T patent/ES2909071T3/es active Active
- 2015-12-10 LT LTEPPCT/EP2015/079208T patent/LT3256125T/lt unknown
- 2015-12-10 MY MYPI2017702097A patent/MY188764A/en unknown
- 2015-12-10 AU AU2015359346A patent/AU2015359346B2/en active Active
- 2015-12-10 KR KR1020217032617A patent/KR102590068B1/ko active IP Right Grant
- 2015-12-10 SG SG11201704563RA patent/SG11201704563RA/en unknown
- 2015-12-10 JP JP2017531167A patent/JP6244497B1/ja active Active
- 2015-12-10 EP EP22152212.1A patent/EP4056179A1/en active Pending
- 2015-12-10 PL PL15807916T patent/PL3256125T3/pl unknown
- 2015-12-10 RS RS20220283A patent/RS63048B1/sr unknown
- 2015-12-10 KR KR1020237034975A patent/KR20230147768A/ko not_active Application Discontinuation
- 2015-12-10 HU HUE15807916A patent/HUE057865T2/hu unknown
- 2015-12-10 PT PT158079160T patent/PT3256125T/pt unknown
2017
- 2017-06-06 IL IL252727A patent/IL252727B/en active IP Right Grant
- 2017-06-07 PH PH12017501059A patent/PH12017501059A1/en unknown
- 2017-06-08 CL CL2017001457A patent/CL2017001457A1/es unknown
- 2017-07-10 ZA ZA2017/04624A patent/ZA201704624B/en unknown
2019
- 2019-01-29 US US16/261,327 patent/US10857134B2/en active Active
2020
- 2020-04-22 AU AU2020202684A patent/AU2020202684A1/en not_active Abandoned
- 2020-11-05 US US17/090,756 patent/US11771683B2/en active Active
2022
- 2022-04-07 CY CY20221100260T patent/CY1125170T1/el unknown
- 2022-05-09 NL NL301174C patent/NL301174I2/nl unknown
- 2022-05-12 HU HUS2200021C patent/HUS2200021I1/hu unknown
- 2022-05-20 LT LTPA2022505C patent/LTPA2022505I1/lt unknown
- 2022-06-01 FR FR22C1021C patent/FR22C1021I2/fr active Active
- 2022-06-10 NO NO2022023C patent/NO2022023I1/no unknown
- 2022-10-13 US US18/046,492 patent/US20230131600A1/en active Pending

Also Published As

Publication number	Publication date
AU2015359346B2 (en)	2020-05-07
US20230131600A1 (en)	2023-04-27
CN117137912A (zh)	2023-12-01
HUS2200021I1 (hu)	2022-05-28
NO2022023I1 (no)	2022-06-10
SI3256125T1 (sl)	2022-04-29
MX2017007638A (es)	2017-09-11
DK3256125T3 (da)	2022-03-21
ES2909071T3 (es)	2022-05-05
IL252727A0 (en)	2017-08-31
EP3256125A1 (en)	2017-12-20
LTPA2022505I1 (pl)	2022-06-10
UA122064C2 (uk)	2020-09-10
KR102590068B1 (ko)	2023-10-16
JP2017538706A (ja)	2017-12-28
HRP20220359T1 (hr)	2022-05-13
SG11201704563RA (en)	2017-07-28
MY188764A (en)	2021-12-30
NZ768672A (en)	2023-10-27
US10857134B2 (en)	2020-12-08
RS63048B1 (sr)	2022-04-29
US20210052555A1 (en)	2021-02-25
PH12017501059A1 (en)	2017-11-27
US20190151292A1 (en)	2019-05-23
EP3256125B1 (en)	2022-01-26
ZA201704624B (en)	2022-03-30
KR102427123B1 (ko)	2022-07-28
US20170319555A1 (en)	2017-11-09
NL301174I1 (pl)	2022-05-09
CN106999461A (zh)	2017-08-01
FR22C1021I2 (fr)	2023-04-14
NZ733463A (en)	2023-10-27
CL2017001457A1 (es)	2018-02-09
KR20210126792A (ko)	2021-10-20
MX2020011182A (es)	2022-10-03
AU2020202684A1 (en)	2020-05-14
US10220023B2 (en)	2019-03-05
HRP20220359T8 (hr)	2022-05-27
FR22C1021I1 (fr)	2022-07-15
JP6244497B1 (ja)	2017-12-06
LT3256125T (lt)	2022-04-11
KR20200013086A (ko)	2020-02-05
KR20230147768A (ko)	2023-10-23
CA2968180A1 (en)	2016-06-16
EA036075B1 (ru)	2020-09-23
EP4056179A1 (en)	2022-09-14
NL301174I2 (nl)	2022-06-09
IL252727B (en)	2021-02-28
EA201791286A1 (ru)	2017-12-29
AU2015359346A8 (en)	2017-08-03
HUE057865T2 (hu)	2022-06-28
PT3256125T (pt)	2022-05-06
US11771683B2 (en)	2023-10-03
CY1125170T1 (el)	2022-07-22
CA2968180C (en)	2020-01-28
KR20170094335A (ko)	2017-08-17
WO2016091996A1 (en)	2016-06-16
AU2015359346A1 (en)	2017-07-27
US20180147188A9 (en)	2018-05-31
TW201625242A (zh)	2016-07-16

Publication	Publication Date	Title
HUS2200021I1 (hu)	2022-05-28	A poneszimodra, egy szelektív S1P1 receptor agonistára vonatkozó adagolási rend
HK1257825A1 (zh)	2019-11-01	檢測網絡內的位置
IL252257A0 (en)	2017-07-31	Insulin receptor partial agonists
IL288907A (en)	2022-02-01	A pharmaceutical combination containing a selective s1p1 receptor agonist
SG11201700669RA (en)	2017-02-27	Arranging a transport service for multiple users
HRP20181570T1 (hr)	2018-11-30	Režim doziranja spoja fgf-18
GB2540877B (en)	2021-01-20	A dosing apparatus
RS61323B1 (sr)	2021-02-26	Dozirna pumpa za dozirni uređaj kao i dozirni uređaj
GB2537080B (en)	2021-02-03	A dosing device
GB201720519D0 (en)	2018-01-24	Dosing regimen
GB201718106D0 (en)	2017-12-13	Dosing regimen
GB201718000D0 (en)	2017-12-13	Dosing regimen
GB201717694D0 (en)	2017-12-13	Dosing regimen
AU2017903935A0 (en)	2017-10-19	Metabolite inspired selective oxytocin receptor agonists
GB201609758D0 (en)	2016-07-20	Dosing Regimen
GB201501974D0 (en)	2015-03-25	Network subscription for a new device
GB201420410D0 (en)	2014-12-31	E-Liquid filling machine